Modeling and simulation of the endogenous CYP3A induction marker 4β-hydroxycholesterol during enasidenib treatment

• Main Authors: Li Y (Author), Connarn JN (Author), Chen J (Author), Tong Z (Author), Palmisano M (Author), Zhou S (Author)
• Format: Book
• Published: Dove Medical Press, 2019-02-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Yan Li,1 Jamie N Connarn,1 Jian Chen,2 Zeen Tong,2 Maria Palmisano,1 Simon Zhou1 1Translational Development and Clinical Pharmacology, Celgene Corporation, Summit, NJ, USA; 2Non-Clinical Development, Celgene Corporation, Summit, NJ, USA Background: Enasidenib (IDHIFA®, AG-221) is a first-in-class, t...